Product Name :
SLC13A5-IN-1
Description:
SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of 14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5.
CAS:
2227548-95-8
Molecular Weight:
461.79
Formula:
C19H19Cl3N2O3S
Chemical Name:
N-[(4-chlorophenyl)methyl]-1-(3, 5-dichlorophenyl)sulfonylpiperidine-4-carboxamide
Smiles :
O=C(NCC1C=CC(Cl)=CC=1)C1CCN(CC1)S(=O)(=O)C1C=C(Cl)C=C(Cl)C=1
InChiKey:
NPEIWANTVUZMJV-UHFFFAOYSA-N
InChi :
InChI=1S/C19H19Cl3N2O3S/c20-15-3-1-13(2-4-15)12-23-19(25)14-5-7-24(8-6-14)28(26,27)18-10-16(21)9-17(22)11-18/h1-4,9-11,14H,5-8,12H2,(H,23,25)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Allopurinol} site|{Allopurinol} Metabolic Enzyme/Protease|{Allopurinol} Biological Activity|{Allopurinol} Formula|{Allopurinol} custom synthesis|{Allopurinol} Autophagy}
Shelf Life:
≥12 months if stored properly.{{Bliretrigine} MedChemExpress|{Bliretrigine} Membrane Transporter/Ion Channel|{Bliretrigine} Protocol|{Bliretrigine} In Vitro|{Bliretrigine} manufacturer|{Bliretrigine} Autophagy}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:24238415
Additional information:
SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of 14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5.|Product information|CAS Number: 2227548-95-8|Molecular Weight: 461.79|Formula: C19H19Cl3N2O3S|Chemical Name: N-[(4-chlorophenyl)methyl]-1-(3, 5-dichlorophenyl)sulfonylpiperidine-4-carboxamide|Smiles: O=C(NCC1C=CC(Cl)=CC=1)C1CCN(CC1)S(=O)(=O)C1C=C(Cl)C=C(Cl)C=1|InChiKey: NPEIWANTVUZMJV-UHFFFAOYSA-N|InChi: InChI=1S/C19H19Cl3N2O3S/c20-15-3-1-13(2-4-15)12-23-19(25)14-5-7-24(8-6-14)28(26,27)18-10-16(21)9-17(22)11-18/h1-4,9-11,14H,5-8,12H2,(H,23,25)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|SLC13A5-IN-1 exhibits an IC50 of 0.022 μM in HepG2/14C-Citrate Uptake Assay. HepG2 cells endogenously express hSLC13A5 transporter which is responsible for the uptake of citrate into these cells. Uptake of 14C-citrate can be completely blocked by SLC13A5-IN-1 and the signal can be competed with unlabelled citrate. T. SLC13A5-IN-1 exhibits an IC50 of 0.056 μM in recombinant hSLC3A5/14C-Citrate Uptake Assay. SLC13A5-IN-1 exhibits an IC50 of 100 μM in recombinant Human GlyT2/3H-Glycine Uptake Assay. The human embryonic kidney 293 cells are used that stably over-express the human GlyT2 receptor which is responsible for the uptake of glycine into these cells. Uptake of 3H-glycine can be completely blocked by SLC13A5-IN-1.|Products are for research use only. Not for human use.|